Editas Medicine (EDIT) Amortizatization of Intangibles (2022 - 2025)
Editas Medicine (EDIT) reported Amortizatization of Intangibles of $62000.0 for Q3 2025, down 95.32% year-over-year from $1.3 million in Q3 2024, and down 75.88% quarter-over-quarter from $257000.0 in Q2 2025.
Editas Medicine (EDIT) Amortizatization of Intangibles (2022 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 4 years of Amortizatization of Intangibles data on file, last reported at $62000.0 in Q3 2025.
- Amortizatization of Intangibles for Q3 2025 came in at $62000.0, down 95.32% year-over-year; the trailing twelve-month figure through Sep 2025 was $1.8 million (down 74.79% YoY), and the FY2024 annual result was $5.8 million, up 20.07% from the prior year.
- Amortizatization of Intangibles retreated to $62000.0 in Q3 2025 per EDIT's latest filing, from $257000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.1 million in Q4 2023 and troughed at $62000.0 in Q3 2025.
- A 4-year average of $1.0 million and a median of $824500.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles jumped 322.29% in 2023, then slumped 95.32% in 2025.
- A 4-year view of Amortizatization of Intangibles shows it stood at $498000.0 in 2022, then jumped by 322.29% to $2.1 million in 2023, then slumped by 58.68% to $869000.0 in 2024, then tumbled by 92.87% to $62000.0 in 2025.
- Business Quant data shows EDIT's Amortizatization of Intangibles at $62000.0 in Q3 2025, $257000.0 in Q2 2025, and $583000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 62,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 257,000.00 |
| Jun 30, 2025 | 257,000.00 |
| Mar 31, 2025 | 583,000.00 |
| Mar 31, 2025 | 583,000.00 |
| Dec 31, 2024 | 869,000.00 |
| Dec 31, 2024 | 869,000.00 |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 780,000.00 |
| Jun 30, 2023 | 780,000.00 |